title: Does PTH offer additive value to ALP measurement in assessing CKD-MBD?
authors.affiliation: Clinical Biochemistry, Kent Kidney Care Centre, East Kent Hospitals University NHS Foundation Trust, Canterbury, Kent, CT1 3NG, UK elamb@nhs.net.
authors.forename: Edmund J
authors.initials: EJ
authors.lastname: Lamb
authors.affiliation: Clinical Biochemistry, Kent Kidney Care Centre, East Kent Hospitals University NHS Foundation Trust, Canterbury, Kent, CT1 3NG, UK.
authors.forename: Michael P
authors.initials: MP
authors.lastname: Delaney
mesh_terms: D000469:Alkaline Phosphatase / Q000032:analysis / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D001851:Bone Diseases, Metabolic / Q000150:complications / Q000175:diagnosis* / Q000628:therapy; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010281:Parathyroid Hormone / Q000032:analysis / Q000097:blood*; D011237:Predictive Value of Tests; D051436:Renal Insufficiency, Chronic / Q000150:complications / Q000175:diagnosis* / Q000628:therapy; D012680:Sensitivity and Specificity
chemical_list: D015415:Biomarkers; D010281:Parathyroid Hormone; D000469:Alkaline Phosphatase